



## **OXB** **Total Voting Rights**

**Oxford, UK - 03 November 2025:** OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as at the close of business on 31 October 2025 consisted of 120,497,010 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in OXB at the date of this notice is 120,497,010.

The above figure 120,497,010 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, OXB under the FCA's Disclosure Guidance and Transparency Rules.

**-Ends-**

### **Enquiries:**

#### **OXB:**

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: [cosec@oxb.com](mailto:cosec@oxb.com)

#### **ICR Healthcare:**

T: +44 (0)20 3709 5700 / E: [oxb@icrhealthcare.com](mailto:oxb@icrhealthcare.com)

Mary-Jane Elliott / Angela Gray / Davide Salvi

### **About OXB**

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at [www.oxb.com](http://www.oxb.com), and follow us on [LinkedIn](#) and [YouTube](#).

information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREAEFAELSSFAA